# Petri Bono

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/petri-bono/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,850 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 53 |
| i10-index | 113 |
| Last Known Institution | Faron Pharmaceutical (Finland) |
| OpenAlex ID | https://openalex.org/A5006874570 |
| ORCID iD | https://orcid.org/0000-0003-3963-0416 |
| Works | 280 |

## Researcher papers

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Faron Pharmaceutical (Finland)](https://scholariq.org/institutions/faron-pharmaceutical-finland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.